Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+ Log In Required
    • New Account Checklist Log In Required
  • Planning & Advice
    • What We Offer
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
  • News & Research
    • News
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Trading
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sector Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Account
    • Annuities
    • Life Insurance & Long Term Care
    • Charitable Giving
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


Find Symbol. Opens in new window.
  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Take AstraZeneca's 'fantastic' vaccine, Germany tells sceptical public

BY Reuters
— 7:06 AM ET 02/26/2021

BERLIN, Feb 26 (Reuters) - Germany's government and health chiefs on Friday urged the public to take AstraZeneca's (AZN) coronavirus vaccine, seeking to stem a tide of scepticism about its effectiveness and safety that has left most of the country's supply unused.

Health authorities in some European countries - including Germany - are facing resistance to the vaccine after side-effects including fever and muscle pain led some front-line workers to call in sick, putting extra strain on already-stretched health services.

Germany also recommended that the AstraZeneca (AZN) vaccine be given only to people aged 18 to 64, which critics said was counterproductive to efforts to contain the pandemic. EU regulators have declared it safe for all.

"We strongly recommend it: this vaccine is safe and effective," Health Minister Jens Spahn told a news conference.

"...It protects oneself and others, like both other vaccines," he added, referring to the two other vaccines approved for use by the European Union, from BioNTech /Pfizer and Moderna (MRNA).

The health ministry said this week it had administered only 15% of the shots it has available, confirming concerns that Germans were being selective, slowing vaccination efforts.

Lothar Wieler, the head of Germany's Robert Koch Institute for Infectious Diseases, said data from Britain and Israel, where there had already been extensive vaccination with AstraZeneca's (AZN) drug showed that the product was "very, very effective".

A study of 500,000 vaccinations in Scotland found that the vaccine reduced hospitalisations by 94%, which was "fantastic", and rejecting it would not be "technically, objectively justified", he said.

AstraZeneca's (AZN) lacklustre reception prompted Spahn at the weekend to offer to vaccinate primary school teachers and nursery workers sooner than originally planned.

On the streets of Berlin on Friday, several Germans said they would take it.

"The reports I heard and read about it were definitely positive, not just negative," said Kerstin Schlebthorst. "Yesterday I actually heard one saying it works differently but it is just as safe. I think this has been approached very hysterically."

Wieler also warned the public to be vigilant in upholding social distancing since there was a risk otherwise of undoing progress and triggering a third wave of the epidemic.

"We will eliminate the severity of the disease through vaccination and immunity and protect ourselves from it, but we will not be able to eradicate it," he said. (Reporting by Thomas Escritt and Paul Carrel; Editing by Maria Sheahan and John Stonestreet)

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More MRNA News

  • New York officials downplay concern over new coronavirus variant
    Reuters - 8:54 PM ET 02/25/2021
  • New York officials downplay concern over new coronavirus variant
    Reuters - 6:10 PM ET 02/25/2021
  • US STOCKS-Wall Street ends sharply lower, tech selloff weighs as bond yields climb
    Reuters - 4:40 PM ET 02/25/2021
Fidelity Investments. Copyright 1998–2021 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close